Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PB2452 (Bentracimab) With and Without Ticagrelor Pretreatment in Chinese Healthy Volunteers

Next Previous
X
Search
Trial Profile

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PB2452 (Bentracimab) With and Without Ticagrelor Pretreatment in Chinese Healthy Volunteers

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 25 Jan 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bentracimab (Primary) ; Ticagrelor
  • Indications Haemorrhage
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors PhaseBio Pharmaceuticals

    • Most Recent Events

    • 19 Jan 2024 Status changed from recruiting to discontinued. The study was initially stopped because of Covid-19. Later, it was found that the PK data for the dose of 18000 mg (which was going to be tested in Cohort-5), would be available from the ongoing Phase 3 study of this drug. Hence, the study was terminated.
    • 22 Dec 2021 Status changed from not yet recruiting to recruiting.
    • 19 Aug 2021 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top